Free tool
FAERS Monitor: Leqembi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761269 or its brand name (Leqembi, Lecanemab-Irmb). Reports on generic versions are filed under their own applications.
Reports
3,813
Serious
1,660
44% of reports
Hospitalization
970
Death reported
164
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- amyloid related imaging abnormality-oedema/effusion530
- headache492
- amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits487
- infusion related reaction330
- chills249
- fatigue225
- pyrexia179
- dizziness175
- confusional state172
- nausea156
- cerebral haemorrhage136
- fall118
- amyloid related imaging abnormalities99
- cerebral infarction98
- vomiting95
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2022 | 7 |
| 2023 | 263 |
| 2024 | 1,402 |
| 2025 | 1,364 |
| 2026 | 776 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,346 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| amyloid related imaging abnormality-microhaemorrhages and haemosiderin depositsSignal | 487 | 4588.0 | 4085.9 | 1,217,281 |
| amyloid related imaging abnormality-oedema/effusionSignal | 530 | 4179.9 | 3750.9 | 1,257,872 |
| amyloid related imaging abnormalitiesSignal | 99 | 2495.6 | 1972.5 | 168,304 |
| infusion related reactionSignal | 330 | 27.6 | 24.9 | 8,416 |
| cerebral infarctionSignal | 98 | 22.2 | 18.3 | 1,958 |
| cerebral haemorrhageSignal | 136 | 21.0 | 17.8 | 2,569 |
| chillsSignal | 249 | 11.7 | 10.4 | 2,444 |
| confusional stateSignal | 172 | 5.9 | 5.1 | 696 |
| headacheSignal | 492 | 4.3 | 4.0 | 1,295 |
| pyrexiaSignal | 179 | 2.9 | 2.5 | 217 |
| fall | 118 | 2.0 | 1.6 | 55 |
| dizziness | 175 | 1.9 | 1.7 | 80 |
| fatigue | 225 | 1.6 | 1.4 | 51 |
| vomiting | 95 | 1.1 | 0.9 | 1 |
| nausea | 156 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.